BGM Group Ltd.

Listed Company
BGMCIK 0001779578NasdaqNon-AcceleratedEmerging GrowthPharmaceutical PreparationsE9KYFY ends Sep 30
Period
FY 2024
Revenue
$25.10M
Net Income
$-1.44M
Total Assets
$53.00M
Equity
$42.74M
Shares Out
98.29M
Op. Cash Flow
$544.2K

Business

BGM Group Ltd is a Cayman Islands holding company that conducts its business operations in China through contractual arrangements with Gansu Qilianshan Pharmaceutical Co., Ltd. Main products include oxytetracycline APIs and tablets, licorice extracts and Gan Di Xin®, Ahan® antibacterial paste, heparin sodium preparations, natural sausage casings and organic and organic‑inorganic fertilizers. Key business segments comprise the WFOE (Qilian International Trading (Chengdu)), the VIE Gansu QLS and its subsidiaries (including Ahan, Chengdu QLS and Moshangfa) and strategic technology and biopharmaceutical initiatives. Products are manufactured in China and sold through qualified distributors, dealers and corporate customers across more than 20 provinces in China.

Summary from filing dated 2025-01-27

Financials

Latest annual snapshot (FY2024, period end 2024-09-30). Full statement history unavailable for this entity.

Revenue$25.10M
Net income$-1.44M
Total assets$53.00M
Total liabilities$8.91M
Stockholders' equity$42.74M
Operating cash flow$544.2K

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro